Extracellular ATP and Macropinocytosis: Their Interactive and Mutually Supportive Roles in Cell Growth, Drug Resistance, and EMT in Cancer.
ABC transporters
ATP internalization
Cancer metabolism
Endocytosis
Epithelial–mesenchymal transition
Metastasis
Purinergic receptor signaling
Journal
Sub-cellular biochemistry
ISSN: 0306-0225
Titre abrégé: Subcell Biochem
Pays: United States
ID NLM: 0316571
Informations de publication
Date de publication:
2022
2022
Historique:
entrez:
5
4
2022
pubmed:
6
4
2022
medline:
7
4
2022
Statut:
ppublish
Résumé
Macropinocytosis is one of the major mechanisms by which cancer cells uptake extracellular nutrients from tumor microenvironment (TME) and plays very important roles in various steps of tumorigenesis. We previously reported the unexpected finding that intratumoral and extracellular ATP (eATP), as one of the major drastically upregulated extracellular nutrients and messengers in tumors, is taken up by cancer cells through macropinocytosis in large quantities and significantly contributing to cancer cell growth, survival, and increased resistance to chemo and target drugs. Inhibition of macropinocytosis substantially reduced eATP uptake by cancer cells and slowed down tumor growth in vivo. More recently, we have found the eATP also plays a very important role in inducing epithelial-to-mesenchymal transition (EMT), and that macropinocytosis is an essential facilitator in the induction. Thus, macropinocytosis and eATP, working in coordination, appear to play some previously unrecognized but very important roles in EMT and metastasis. As a result, they are likely to be interactive and communicative with each other, regulating each other's activity for various needs of host tumor cells. They are also likely to be an integral part of the future new anticancer therapeutic strategies. Moreover, it is undoubted that we have not identified all the important activities coordinated by ATP and macropinocytosis. This review describes our findings in how eATP and macropinocytosis work together to promote cancer cell growth, resistance, and EMT. We also list scientific challenges facing eATP research and propose to target macropinocytosis and eATP to reduce drug resistance and slow down metastasis.
Identifiants
pubmed: 35378703
doi: 10.1007/978-3-030-94004-1_4
pmc: PMC9825817
mid: NIHMS1856455
doi:
Substances chimiques
Adenosine Triphosphate
8L70Q75FXE
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
61-83Subventions
Organisme : NCI NIH HHS
ID : R15 CA242177
Pays : United States
Informations de copyright
© 2022. The Author(s), under exclusive license to Springer Nature Switzerland AG.
Références
Cancer Lett. 2014 Sep 1;351(2):242-51
pubmed: 24973521
Physiology (Bethesda). 2007 Apr;22:122-30
pubmed: 17420303
Purinergic Signal. 2013 Dec;9(4):491-540
pubmed: 23797685
Nature. 2012 Oct 18;490(7420):367-72
pubmed: 23000901
J Biol Chem. 2016 Jun 17;291(25):13040-7
pubmed: 27129284
Nat Commun. 2019 Feb 12;10(1):711
pubmed: 30755613
Nat Rev Cancer. 2018 Oct;18(10):619-633
pubmed: 30097614
Annu Rev Physiol. 2020 Feb 10;82:103-126
pubmed: 31730395
Oncogene. 2017 Jan 19;36(3):293-303
pubmed: 27321181
Proc Natl Acad Sci U S A. 1998 Aug 4;95(16):9232-7
pubmed: 9689063
Pathol Int. 2016 Nov;66(11):601-608
pubmed: 27510923
Cold Spring Harb Perspect Biol. 2012 May 01;4(5):
pubmed: 20739415
Exp Oncol. 2013 Dec;35(4):287-90
pubmed: 24382439
Philos Trans R Soc Lond B Biol Sci. 2019 Feb 4;374(1765):20180153
pubmed: 30967003
Int J Mol Sci. 2019 Jun 05;20(11):
pubmed: 31195692
BMC Cell Biol. 2008 Oct 14;9:58
pubmed: 18854019
J Cell Sci. 2015 Dec 1;128(23):4407-19
pubmed: 26459636
Cell Metab. 2016 Jan 12;23(1):27-47
pubmed: 26771115
PLoS One. 2013;8(4):e59778
pubmed: 23577075
J Biol Chem. 2009 May 1;284(18):12110-24
pubmed: 19265192
Cancer Treat Rev. 2009 Dec;35(8):707-13
pubmed: 19758758
J Biol Chem. 1988 Feb 25;263(6):2962-8
pubmed: 2449431
PLoS One. 2012;7(6):e40069
pubmed: 22768222
Gene Expr. 1998;7(2):75-86
pubmed: 9699480
J Immunol. 2011 Apr 1;186(7):4375-87
pubmed: 21357533
Nat Cell Biol. 2009 May;11(5):510-20
pubmed: 19404330
Methods Mol Biol. 2016;1417:115-29
pubmed: 27221485
Free Radic Biol Med. 2015 Feb;79:253-63
pubmed: 25277420
Science. 2011 Dec 16;334(6062):1573-7
pubmed: 22174255
Cell Death Differ. 2014 Jan;21(1):79-91
pubmed: 23852373
Int J Mol Sci. 2021 Mar 04;22(5):
pubmed: 33806300
Cancer Lett. 2010 Dec 8;298(2):176-85
pubmed: 20678861
Dev Cell. 2009 Jul;17(1):9-26
pubmed: 19619488
PLoS One. 2017 Sep 20;12(9):e0184588
pubmed: 28931067
PLoS One. 2017 Nov 9;12(11):e0187481
pubmed: 29121644
PLoS One. 2008 Jul 09;3(7):e2599
pubmed: 18612415
Nat Protoc. 2017 Aug;12(8):1542-1562
pubmed: 28683062
PLoS One. 2018 Mar 28;13(3):e0193779
pubmed: 29590154
Am J Pathol. 2019 Feb;189(2):354-369
pubmed: 30448410
Nat Rev Clin Oncol. 2017 Oct;14(10):611-629
pubmed: 28397828
Cancer Res. 2012 Jan 1;72(1):304-14
pubmed: 22084398
J Nucl Med. 2010 Aug;51(8):1167-70
pubmed: 20660380
Science. 2017 May 19;356(6339):753-756
pubmed: 28522535
Int J Oncol. 2015 Sep;47(3):840-8
pubmed: 26202679
Int J Oncol. 2017 Nov;51(5):1357-1369
pubmed: 29048660
Curr Pharm Des. 2015;21(10):1279-91
pubmed: 25506898
Nat Med. 2004 Mar;10(3):310-5
pubmed: 14770178
Acta Crystallogr D Biol Crystallogr. 2011 Dec;67(Pt 12):1073-5
pubmed: 22120745
Cancer Drug Resist. 2020;3(1):38-47
pubmed: 32226927
React Oxyg Species (Apex). 2018 Mar;5(14):118-125
pubmed: 29780885
Front Endocrinol (Lausanne). 2017 Sep 29;8:261
pubmed: 29085336
Proc Natl Acad Sci U S A. 2016 Aug 30;113(35):9786-91
pubmed: 27528667
Cancer Cell Int. 2019 Oct 01;19:254
pubmed: 31582910
J Cell Sci. 2017 Feb 15;130(4):663-669
pubmed: 28202602
Curr Opin Pharmacol. 2016 Aug;29:17-25
pubmed: 27262778
Front Neurosci. 2015 Apr 28;9:148
pubmed: 25972780
Int J Mol Sci. 2017 Dec 01;18(12):
pubmed: 29194401
Mol Cancer Ther. 2012 Aug;11(8):1672-82
pubmed: 22689530
Cancer Cell Int. 2020 Apr 7;20:110
pubmed: 32280302
Mol Carcinog. 2014 Apr;53(4):253-63
pubmed: 23073998
FEBS J. 2017 Oct;284(19):3132-3144
pubmed: 28444969
RSC Adv. 2018 Jun 19;8(39):22182-22192
pubmed: 35541713
Mol Pharmacol. 2020 Feb;97(2):72-89
pubmed: 31787618
Nat Protoc. 2014 Jan;9(1):182-92
pubmed: 24385148
Front Immunol. 2017 Aug 11;8:979
pubmed: 28848564
Proc Natl Acad Sci U S A. 2016 Aug 2;113(31):8711-6
pubmed: 27439870
Stem Cells Int. 2018 Feb 28;2018:5416923
pubmed: 29681949
Cancer Lett. 2014 Jun 1;347(2):159-66
pubmed: 24657660
J Cell Biol. 2002 Sep 16;158(6):1119-31
pubmed: 12221069
Prostate. 2017 May;77(7):776-793
pubmed: 28181686
Front Oncol. 2020 Jun 25;10:1010
pubmed: 32670883
Cell Res. 2009 Feb;19(2):156-72
pubmed: 19153598
Immunity. 1995 Dec;3(6):783-91
pubmed: 8777723
Philos Trans R Soc Lond B Biol Sci. 2014 Feb 03;369(1638):20130099
pubmed: 24493747
Front Immunol. 2019 Dec 20;10:2854
pubmed: 31921125
Nanomedicine (Lond). 2012 Apr;7(4):597-615
pubmed: 22471722
Trends Biochem Sci. 2020 Jun;45(6):459-461
pubmed: 32413322
Nat Rev Cancer. 2018 Oct;18(10):601-618
pubmed: 30006588
Pharmacol Rev. 2006 Mar;58(1):32-45
pubmed: 16507881
Biochim Biophys Acta. 2015 Sep;1850(9):1905-11
pubmed: 25964069
Cancer Sci. 2019 Aug;110(8):2456-2470
pubmed: 31148343
J Gen Physiol. 2014 Apr;143(4):419-35
pubmed: 24638992
J Biol Inorg Chem. 2013 Feb;18(2):165-74
pubmed: 23183891
Cancer Metastasis Rev. 2019 Jun;38(1-2):113-129
pubmed: 30607627
Nat Rev Mol Cell Biol. 2015 Mar;16(3):190-202
pubmed: 25650800
Front Physiol. 2015 Jan 30;6:1
pubmed: 25688210
Philos Trans R Soc Lond B Biol Sci. 2019 Feb 4;374(1765):20180285
pubmed: 30967008
Bioorg Med Chem Lett. 2010 Apr 1;20(7):2191-4
pubmed: 20194024
Sci Signal. 2009 Feb 03;2(56):pe6
pubmed: 19193605
Philos Trans R Soc Lond B Biol Sci. 2019 Feb 4;374(1765):20180146
pubmed: 30967000
Trends Pharmacol Sci. 2017 Mar;38(3):277-290
pubmed: 27989503
Front Physiol. 2017 Jun 06;8:371
pubmed: 28634454
Curr Drug Targets. 2011 May;12(5):600-20
pubmed: 21039335
Explor Target Antitumor Ther. 2020;1(2):71-100
pubmed: 36046070
Cells. 2020 Nov 17;9(11):
pubmed: 33212982
Traffic. 2013 Jul;14(7):739-48
pubmed: 23387372
Cell Res. 2013 Aug;23(8):982-3
pubmed: 23774265
Oncotarget. 2017 Sep 23;8(50):87860-87877
pubmed: 29152126
Purinergic Signal. 2012 Mar;8(1):39-48
pubmed: 21818572
Cancer Res. 2010 Feb 1;70(3):855-8
pubmed: 20086177
Immunol Cell Biol. 2011 Nov;89(8):836-43
pubmed: 21423264
Oncogene. 2017 Mar;36(11):1461-1473
pubmed: 27617575
Nat Commun. 2020 Feb 28;11(1):1121
pubmed: 32111826
Cancer Drug Resist. 2019;2:141-160
pubmed: 34322663
Nat Rev Cancer. 2011 May;11(5):325-37
pubmed: 21508971
J Cell Sci. 2006 Oct 1;119(Pt 19):3967-80
pubmed: 16968745
Nature. 2013 May 30;497(7451):633-7
pubmed: 23665962
Int J Mol Sci. 2019 Apr 25;20(8):
pubmed: 31027222
J Oncol. 2019 Apr 1;2019:2343876
pubmed: 31057611
J Cell Sci. 2016 Jul 15;129(14):2697-705
pubmed: 27352861
Cold Spring Harb Perspect Biol. 2012 Jul 01;4(7):a006742
pubmed: 21441585
Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9714-9
pubmed: 15980154
Mol Cancer Res. 2016 Nov;14(11):1087-1096
pubmed: 27578770
J Cell Sci. 2012 Nov 1;125(Pt 21):5051-60
pubmed: 22946048
Nat Rev Mol Cell Biol. 2018 Jul;19(7):464-478
pubmed: 29740129
Oncogene. 2019 Jan;38(2):194-208
pubmed: 30087439
Science. 2000 May 26;288(5470):1418-22
pubmed: 10827951
Membranes (Basel). 2020 Aug 03;10(8):
pubmed: 32756454
Curr Opin Oncol. 2013 Jan;25(1):76-84
pubmed: 23197193
PLoS Genet. 2013 Apr;9(4):e1003407
pubmed: 23637612
Onco Targets Ther. 2015 Oct 16;8:2973-80
pubmed: 26527883
Science. 2016 Jun 3;352(6290):1221-5
pubmed: 27257257
J Vis Exp. 2009 Apr 29;(26):
pubmed: 19404236
Proc Natl Acad Sci U S A. 2020 Nov 3;117(44):27400-27411
pubmed: 33087579
Biol Bull. 2016 Aug;231(1):73-84
pubmed: 27638696
F1000Res. 2018 Sep 18;7:
pubmed: 30271576
Nat Med. 2010 Dec;16(12):1434-8
pubmed: 21102458
Front Immunol. 2018 Oct 02;9:2286
pubmed: 30333835
Interface Focus. 2013 Jun 6;3(3):20120101
pubmed: 23853707
Prostate. 2018 Jul 11;:
pubmed: 29992622
Biosens Bioelectron. 2013 May 15;43:355-61
pubmed: 23357001